WILLIAMS AND JENSEN, PLLC for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
General education about FDA approval policies and NIH research activities.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox |
Taxation/Internal Revenue Code TAX
Orphan drug tax credit issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | Sch C, Treasury; LD, Rep Scott McInnis |
| CHERYL LYNN JAEGER | Shd employee, Ofc of the Speaker 7 Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox |
Health Issues HCR
General education about policies impacting pharmaceutical development, approval, and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox |
Medicare/Medicaid MMM
General education about policies impacting pharmaceutical development, approval, reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox |
Budget/Appropriations BUD
Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHERYL LYNN JAEGER New | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Republican Whip, Rep Cantor; Sr Policy Adv, Majority Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.